Symptoms, lung function, and beta2-adrenoceptor polymorphisms in a birth cohort followed for 10 years

Nicola M Wilson1, Jane R Lamprill, Judith C W Mak

  • 1Department of Paediatrics, National Heart and Lung Institute, London, UK. n.wilson@rbh.nthames.nhs.uk

Insights

Neonatal bronchial responsiveness predicts early wheezing and later lung function in children at risk of allergy. However, wheezing after age four, indicative of asthma, was not linked to early measurements.

Area of Science:

  • Pediatric Pulmonology
  • Allergy and Immunology
  • Genetics

Background:

  • The natural history of bronchial responsiveness and childhood wheezing is poorly understood.
  • Early childhood allergy risk and neonatal respiratory measurements are key areas for investigation.

Purpose of the Study:

  • To determine the impact of neonatal measurements on wheezing history and lung function over 10 years.
  • To explore the role of beta-2 adrenoceptor (beta2AR) gene polymorphisms in these associations.

Main Methods:

  • Prospective follow-up of 73 children at allergy risk for 10 years.
  • Measurement of lung function and bronchial responsiveness in neonates and at age 10.
  • Categorization of wheezing history and genotyping of beta2AR polymorphisms.

Main Results:

  • Neonatal bronchial responsiveness predicted later FEV1 (forced expiratory volume in 1 second) and was associated with transient wheeze before age 4.
  • Wheezing after age 4, characteristic of asthma, correlated with atopy and bronchial responsiveness at age 10.
  • Neonatal V'maxFRC (maximal flow rate at functional residual capacity) was affected by specific beta2AR polymorphisms (Gln27, Arg16), but these did not impact 10-year FEV1.

Conclusions:

  • Neonatal bronchial responsiveness is linked to early wheezing and subsequent lung function.
  • Beta-2 adrenoceptor polymorphisms influence neonatal lung function.
  • Late-onset wheezing (after age 4) aligns with classical asthma and is independent of early respiratory measurements.

Related Concept Videos

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features01:24

Chronic Obstructive Pulmonary Disease III: Chronic Bronchitis Features

Chronic bronchitis is a key phenotype of chronic obstructive pulmonary disease (COPD), characterized by airway-centered inflammation and mucus overproduction. It develops from long-term exposure to harmful particles or gases, most commonly cigarette smoke, which triggers a persistent inflammatory response.Cellular and Structural ChangesInflammation initially affects the large bronchi and later the smaller airways, with infiltration by immune cells, including neutrophils, macrophages, and...
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Chronic Obstructive Pulmonary Disease I: Introduction01:23

Chronic Obstructive Pulmonary Disease I: Introduction

Chronic obstructive pulmonary disease is a common, preventable, and treatable respiratory disorder characterized by persistent symptoms and progressive airflow limitation. This limitation results from a combination of small-airway disease (obstructive bronchiolitis) and parenchymal destruction (emphysema), both driven by chronic inflammation from exposure to harmful particles or gases.The disease includes two main pathological entities: emphysema, marked by destruction of alveolar walls and...
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
Chronic Obstructive Pulmonary Disease II: Emphysema01:23

Chronic Obstructive Pulmonary Disease II: Emphysema

Emphysema, a major phenotype of chronic obstructive pulmonary disease (COPD), is characterized by irreversible destruction of alveolar walls and permanent enlargement of distal airspaces. Unlike chronic bronchitis, which primarily affects the airways, emphysema predominantly involves the lung parenchyma, where structural damage leads to airflow limitation.PathophysiologyIt most commonly results from prolonged exposure to cigarette smoke and other toxic gases, particularly cigarette smoke.